Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process

Journal of Pharmacy and Pharmacology

Volumn 63, Issue 4, 2011, Pages 491-499

  Park, Jae Hyun ^a,b   Yan, Yi Dong ^c   Chi, Sang Cheol ^a   Hwang, Doo Hyung ^c   Shanmugam, Srinivasan ^a,c   Lyoo, Won Seok ^c   Woo, Jong Soo ^b,c   Yong, Chul Soon ^c   Choi, Han Gon ^c,d  

^a Sungkyunkwan University   (South Korea)

^b Hanmi Pharmaceutical Co Ltd   (South Korea)

^c Yeungnam University   (South Korea)

^d Hanyang University   (South Korea)

Author keywords

Cremophor el; Paclitaxel; Solid dispersion; Supercritical fluid

Indexed keywords

CARBON DIOXIDE; CREMOPHOR; PACLITAXEL; SODIUM CHLORIDE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; IN VIVO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOANALYSIS; NONHUMAN; ORGAN DISTRIBUTION; PARTICLE SIZE; PHYSICAL CHEMISTRY; PROCESS DEVELOPMENT; RAT; SCANNING ELECTRON MICROSCOPY; SOLID STATE; TEMPERATURE STRESS; X RAY DIFFRACTION;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; GLYCEROL; INJECTIONS, INTRAVENOUS; MALE; NANOTECHNOLOGY; PACLITAXEL; RATS; RATS, SPRAGUE-DAWLEY; SOLUBILITY; TISSUE DISTRIBUTION;

EID: 79952725911     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2010.01218.x     Document Type: Article

References (28)

1. Rowinsky EK, Donehower DRG. Drug therapy - paclitaxel (Taxol). N Engl J Med 1995; 332: 1004-1014.
2. Wall EM, Wani MC. Camptothecin and taxol: discovery to clinic - thirteenth Bruce F. Cain memorial award lecture. Cancer Res 1995; 55: 753-760.
3. Straubinger RM et al. Taxane Anticancer Agents. Washington, DC: ACS, 1995.
4. Mukherjee T, Plakogiannis FM. Development and oral bioavailability assessment of a supersaturated self-microemulsifying drug delivery system (SMEDDS) of albendazole. J Pharm Pharmacol 2010; 62: 1112-1120.
5. Pahala S, Dannenfelser RM. Emulsion formulations for intravenous administration of paclitaxel. PDA J Pharm Sci Technol 1998; 52: 170-172.
6. Alkan OH et al. A mixed micellar formulation suitable for the parenteral administration of Taxol®. Pharm Res 1994; 11: 206-212.
7. Shieh MF et al. Liposomal delivery system for taxol. J Ferment Bioeng 1997; 83: 12-15.
8. Bilensoy E et al. Safety and efficacy of amphiphilic β-cyclodextrin nanoparticles for paclitaxel delivery. Int J Pharm 2008; 347: 163-170. (Pubitemid 350180328)
9. Dordunoo SK et al. Taxol® encapsulation in poly(e-caprolacton) microspheres. Cancer Chemother Pharmacol 1995; 36: 279-282.
10. Tarr BD et al. A new parenteral emulsion for the administration of taxol. Pharm Res 1987; 4: 162-165. (Pubitemid 17089608)
11. Kang Y et al. Preparation of PLLA/PLGA microparticles using solution enhanced dispersion by supercritical fluids (SEDS). J Colloid Interf Sci 2008; 322: 87-94.
12. Lee LY et al. Supercritical antisolvent production of biodegradable micro- and nanoparticles for controlled delivery of paclitaxel. J Controlled Release 2008; 125: 96-106. (Pubitemid 350299604)
13. Lee MK et al. Preparation, characterization and in vitro cytotoxicity of paclitaxel loaded sterically stabilized solid lipid nanoparticles. Biomaterials 2007; 28: 2137-2146.
14. Kompella UB, Koushik K. Preparation of drug delivery systems using supercritical fluid technology. Crit Rev Ther Drug Carrier Syst 2001; 18: 173-199. (Pubitemid 32378147)
15. Jung J, Perrut M. Particle design using supercritical fluids: literature and patent survey. J Supercrit Fluids 2001; 20: 179-219. (Pubitemid 32607129)
16. Society of Toxicology (SOT). Guiding principles in the use of animals in toxicology. 2008. http://www.toxicology.org/AI/FA/ guidingprinciples.pdf.
17. Katzenstein R et al. Localization and associated changes following intravenous injection of some non-metabolizable colloids. Yale J Biol Med 1994; 16: 561-570.
18. Katzenstein R et al. Renal disease consequent upon the intravenous injection of low viscosity methyl cellulose. Yale J Biol Med 1994; 16: 571-578.
19. Won DH et al. Improved physicochemical characteristics of felodipine solid dispersion particles by supercritical anti-solvent precipitation process. Int J Pharm 2005; 301: 199-208.
20. Nazzal S et al. Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formulation. Int J Pharm 2002; 235: 247-265. (Pubitemid 34185455)
21. Ruan LP et al. Improving the solubility of ampelopsin by solid dispersions and inclusion complexes. J Pharm Biomed Anal 2005; 38: 457-464.
22. Ficarra R et al. Study of flavonoids/β-cyclodextrins inclusion complexes by NMR, FT-IR, DSC, X-ray investigation. J Pharm Biomed Anal 2002; 29: 1005-1014. (Pubitemid 34756653)
23. Ford JL. The current status of solid dispersions. Pharm Acta Helv 1986; 61: 69-88. (Pubitemid 16134014)
24. Fernandes CM et al. Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci 2002; 15: 79-88. (Pubitemid 34136971)
25. Mura P et al. Influence of the preparation method on the physicochemical properties of ketoprofen-cyclodextrin binary system. Int J Pharm 1999; 179: 117-128. (Pubitemid 29115066)
26. Rowinsky EK, Donehower RG. The clinical pharmacology of paclitaxel (TAXOL®). Semin Oncol 1993; 20: 16-25.
27. Sparreboom A et al. Tissue distribution, metabolism and excretion of paclitaxel in mice. Anticancer Drugs 1996; 7: 78-86. (Pubitemid 26059949)
28. Jae HPP et al. Toxicity studies of cremophor-free paclitaxel solid dispersion formulated by a supercritical antisolvent process. Arch Pharm Res 2009; 32: 139-148.